Arcturus Therapeutics Holdings Inc.
ARCTNasdaq
$6.05
↓ -2.1%Jul 17 close · end-of-day
Price
1Y↓ -52.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$171.9M
Enterprise Value
-$39.4M
P/E
—
P/S
3.1
P/B
0.9
EV/EBITDA
—
PEG
—
FCF Yield
-34.1%
Dividend Yield
—
Revenue (TTM)
$54.7M
Net Income (TTM)
-$78.7M
Free Cash Flow (TTM)
-$58.7M
Gross Margin
—
Operating Margin
-161.5%
Net Margin
-143.8%
ROE
-41.1%
ROIC
—
Debt / Equity
—
Net Cash
$211.4M
Return 1Y
-55.3%
Company profile
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNar-CF program for cystic fibrosis lung disease. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines.
- CEO
- Joseph E. Payne
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 180
- Headquarters
- California
- Website
- arcturusrx.com
Earnings
ARCT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.1M↓ -93.0%
Diluted EPS-$0.95↑ +82.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.5M | $12.4M | $206.0M | $166.8M | $152.3M | $82.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$71.5M | -$202.9M | $12.2M | -$78.2M | -$95.7M | -$76.3M |
| Net income | -$72.1M | -$203.7M | $9.3M | -$29.7M | -$80.9M | -$65.8M |
| Diluted EPS | — | -$7.74 | $0.35 | -$1.12 | -$3.00 | -$2.40 |
| Operating cash flow | -$42.9M | -$135.0M | $32.0M | -$18.1M | -$59.7M | -$74.3M |
| Free cash flow | -$44.6M | -$138.4M | $24.3M | -$21.0M | -$60.4M | -$74.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -749.8% | -1641.3% | 5.9% | -46.9% | -62.8% | -93.0% |
| Net margin | -756.3% | -1648.0% | 4.5% | -17.8% | -53.1% | -80.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49.9M | $41.7M | $22.8M | $29.4M | $28.3M | $17.2M | $7.2M | $2.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$21.1M | -$10.7M | -$33.4M | -$16.8M | -$11.6M | -$16.5M | -$31.3M | -$28.9M |
| Net income | -$17.2M | -$6.9M | -$30.0M | -$14.1M | -$9.2M | -$13.4M | -$29.1M | -$27.0M |
| Diluted EPS | -$0.64 | -$0.26 | -$1.10 | -$0.52 | -$0.34 | -$0.49 | -$1.05 | -$0.95 |
| Operating cash flow | -$30.1M | -$23.8M | -$284,000.00 | -$35.1M | -$5.8M | -$17.2M | -$16.2M | -$19.4M |
| Free cash flow | -$30.5M | -$23.8M | -$284,000.00 | -$35.3M | -$5.8M | -$17.3M | -$16.3M | -$19.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -42.4% | -25.8% | -146.7% | -57.3% | -41.0% | -96.3% | -435.0% | -1403.7% |
| Net margin | -34.5% | -16.6% | -131.8% | -47.9% | -32.4% | -78.4% | -404.0% | -1308.3% |
Company news
Jul 3, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-08-15 | SASSINE ANDY· Chief Financial Officer | Buy | 1,238 | $16.56 | $20,498.80 | filing |
| 2025-08-15 | SASSINE ANDY· Chief Financial Officer | Buy | 1,238 | $16.56 | $20,498.80 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.